Navigation Links
Intellect Neurosciences, Inc. and CHDI, Inc. Enter Into Compound Testing Agreement to Evaluate OXIGON(TM) as a Potential Treatment for Huntington Disease
Date:9/20/2007

Agreement demonstrates broad potential use of Intellect's clinical

candidate

NEW YORK, Sept. 20 /PRNewswire-FirstCall/ -- Intellect Neurosciences, Inc. (OTC Bulletin Board: ILNS), a biopharmaceutical company focused on the development of disease-modifying therapeutic agents for the treatment and prevention of Alzheimer's disease and related disorders, and CHDI, Inc., a non-profit organization pursuing the discovery and development of drugs to prevent or slow the progression of Huntington disease (HD), announced today that they have entered into an agreement under which CHDI will assess Intellect's OXIGON(TM) as a potential therapy for Huntington disease. CHDI has access to a variety of relevant research tools, including in vitro and in vivo assays and animal models. Intellect has completed Phase I clinical trials for OXIGON(TM) in elderly healthy volunteers.

Dr. Daniel Chain, CEO and Chairman of Intellect, commented: "We are pleased that CHDI is evaluating whether OXIGON's method of action might extend to Huntington disease. OXIGON(TM) is planned to enter Phase II clinical trials in Alzheimer's patients in 2008. The data generated in the CHDI study could support proceeding with clinical trials in HD patients as well."

"We are intrigued by the properties of this compound, which has demonstrated neuroprotective effects in various animal models," said Robert Pacifici, CHDI's Chief Scientific Officer. "We are pleased to work with the Intellect team to evaluate the usefulness of OXIGON(TM) to treat HD."

About OXIGON(TM)

Intellect's lead drug candidate, OXIGON(TM), is a chemically synthesized form of a naturally occurring molecule that has unique neuroprotectant and antioxidant properties. OXIGON(TM) has been demonstrated to protect the brain from many potent neurotoxins in animals and also to block the formation of toxic aggregates that result from abnormal folding of proteins such as beta amyloid
'/>"/>

SOURCE Intellect Neurosciences, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Genetic Analysis Systems Enter the Clinical Mainstream
2. Annual Meeting of the Consortium of Multiple Sclerosis Centers Focuses on the Challenges of Care and Research in Multiple Sclerosis
3. Breaking Multi-Center Study: Masimo SET Pulse Oximetry Technology Shown to Significantly Lower Instances of Severe Retinopathy of Prematurity in Extremely Low Birth Weight Infants
4. Nuvelo Announces Publication of NU206 Study Results in Gastroenterology
5. GSK and Adolor Announce Preliminary Results from Phase 3 Safety Study of Alvimopan (Entereg/Entrareg)
6. M. D. Anderson Cancer Center Researchers to Present CTCE-9908 Data at the AACR Annual Meeting
7. Ceragenix Compound Shows Promise for Treating Lethal Cystic Fibrosis Infections
8. Neurogen Proprietary Insomnia Compound Data for Two Studies Presented at Associated Professional Sleep Societies Annual Meeting
9. Neurogen Proprietary Insomnia Compound Data Presented at Associated Professional Sleep Societies Annual Meeting
10. Anacor Clinical Study of AN2728, a Novel Anti-Inflammatory Compound, Shows Efficacy in Psoriasis
11. AEterna Zentaris Partner Keryx Presents Phase 1 and Phase 2 Results for Anti-Cancer Compound Perifosine at ASCO Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2014)... Texas , Nov. 26, 2014 ... today announced the completion of previously announced concurrent ... million.  After fees and estimated offering expenses, Lexicon ... the transactions.  The transactions consisted of: ... common stock, pursuant to a registration statement that ...
(Date:11/26/2014)... Calif. , Nov. 26, 2014  Avanir ... that the U.S. Food and Drug Administration (FDA) ... New Drug Application (NDA) for AVP-825. AVP-825 is ... sumatriptan powder delivered intranasally utilizing a novel Breath ... Complete Response letter, and consistent with the preliminary ...
(Date:11/26/2014)... 2014 Investor-Edge has initiated coverage on ... Horizon Pharma PLC (NASDAQ: HZNP ), Endocyte Inc. ... JNJ ), and Theravance Inc. (NASDAQ: THRX ... at: http://investor-edge.com/register . On Tuesday, November 25, ... Dow Jones Industrial Average edged 0.02% lower, to finish the ...
Breaking Medicine Technology:Lexicon Announces Completion Of $280 Million In Financing Transactions 2Lexicon Announces Completion Of $280 Million In Financing Transactions 3Avanir Pharmaceuticals Receives Complete Response Letter (CRL) from FDA on AVP-825 NDA 2Avanir Pharmaceuticals Receives Complete Response Letter (CRL) from FDA on AVP-825 NDA 3Avanir Pharmaceuticals Receives Complete Response Letter (CRL) from FDA on AVP-825 NDA 4Pharma Stocks Highlight - VIVUS, Horizon Pharma, Endocyte, Johnson and Johnson, and Theravance 2Pharma Stocks Highlight - VIVUS, Horizon Pharma, Endocyte, Johnson and Johnson, and Theravance 3Pharma Stocks Highlight - VIVUS, Horizon Pharma, Endocyte, Johnson and Johnson, and Theravance 4Pharma Stocks Highlight - VIVUS, Horizon Pharma, Endocyte, Johnson and Johnson, and Theravance 5
... Sept. 18 A long-term study found,that a ... with life-threatening,diseases, such as leukemia and lymphoma, results ... males are likely to recover,from these changes over ... In addition, neither male nor female long-term cancer,survivors ...
... Bacterial Infection and May ... Bacterial Infections, BOSTON, Sept. 18 Paratek ... of the Company,s,Multiple Adaptation Response (MAR) inhibitor program. ... controlling virulence and antibiotic,resistance. Paratek has shown that ...
Cached Medicine Technology:Sexual Function Affected by Stem Cell Transplant According to Long-Term Study 2Sexual Function Affected by Stem Cell Transplant According to Long-Term Study 3Sexual Function Affected by Stem Cell Transplant According to Long-Term Study 4Promising Data from Paratek Pharmaceuticals' MAR Inhibitor Program Presented in 'Late Breaker' Session at the 47th Interscience Conference on Antimicrobial Agents and Chemotherapy 2Promising Data from Paratek Pharmaceuticals' MAR Inhibitor Program Presented in 'Late Breaker' Session at the 47th Interscience Conference on Antimicrobial Agents and Chemotherapy 3Promising Data from Paratek Pharmaceuticals' MAR Inhibitor Program Presented in 'Late Breaker' Session at the 47th Interscience Conference on Antimicrobial Agents and Chemotherapy 4
(Date:11/28/2014)... Mabel’s Labels , the market ... an award-winning company established by four moms, today announced ... Tricia Mumby have been honored with a 2014 RBC ... PROFIT Award for Excellence in Entrepreneurship. , All 4 ... Mumby) accepted the award on behalf of Mabel’s Labels ...
(Date:11/28/2014)... Everett, WA (PRWEB) November 28, 2014 ... Snohomish County provides an overview of the influenza virus that ... annual flu season. , The article begins with a ... it manifests its symptoms. It reminds families that children under ... and those suffering from chronic diseases, such as heart and ...
(Date:11/28/2014)... FL (PRWEB) November 28, 2014 Lice Troopers ... areas of its in-home head lice service for moms ... in the center of Coral Gables on Pone De-leon Blvd ... Bay Harbor Islands that service Miami-Dade & Broward. Lice ... salon in South Florida which has been treating families for ...
(Date:11/28/2014)... Pittsburgh, PA (PRWEB) November 28, 2014 "Most ... have forced me to use crutches," said an inventor from ... better, more convenient way to support my foot, which inspired ... Foot Sling to offer a convenient way to support an ... to get around. It eliminates the need for crutches. The ...
(Date:11/28/2014)... (PRWEB) November 28, 2014 Schools ... value of providing quality commercial playground equipment to ... selected APCPLAY© to supply an affordable play structure ... City. , Centra provides comprehensive programs for ... and emotional support services. They have served ...
Breaking Medicine News(10 mins):Health News:Mabel's Labels’ Co-Founders Named A Winner In The 2014 RBC Canadian Women Entrepreneur Awards Program; A Second-Time Win For The Brand 2Health News:Mabel's Labels’ Co-Founders Named A Winner In The 2014 RBC Canadian Women Entrepreneur Awards Program; A Second-Time Win For The Brand 3Health News:How Flu Vaccines Can Impact Families Is Discussed in New Article from Community Health Center of Snohomish County 2Health News:Lice Troopers Lice Removal Service Expands in Miami-Dade 2Health News:Centra Rivermont (VA) Provides School Playground Equipment from APCPLAY© for Special Needs Students 2Health News:Centra Rivermont (VA) Provides School Playground Equipment from APCPLAY© for Special Needs Students 3
... people newly diagnosed with HIV in the UK has ... with the transmission of antiretroviral-resistant HIV. // ... Protection Agency have investigated the connection between two phenomena: ... transmission, and the transmission of drug-resistant HIV. Sexually transmitted ...
... & Melinda Gates Foundation and the Medicines for Malaria ... center //in the United Arab Emirates (UAE). The center ... News reports. ,Gates Foundation and MMV representatives ... of Health to discuss the project. The foundation selected ...
... chances of contracting HIV by up to 60 percent, ... at increased risk of infection. // ,Early results ... potential impact of male circumcision on AIDS in Africa ... sex while healing from circumcision surgery, their female partners ...
... Dry Eye Syndrome (DES) has a significant impact on quality ... and 4.7% of men over 50, and affects over //4.8 ... have been identified, the cause of DES is still largely ... the quantity and/or quality of tears, an unstable tear film, ...
... and type 2 diabetes increases the risk of death for ... of heart disease deaths by itself, but together they’ve been ... an analysis of more than 900 patients with established coronary ... with both type 2 diabetes and symptoms of depression were ...
... of life are not sufficiently met and need to be upgraded ... systems do not reliably meet the needs of people living with ... and Joanne Lynn, two palliative care doctors based in the United ... we use language – and build health care systems – as ...
Cached Medicine News:Health News:STIs Significantly Increase Risk of Drug-resistant HIV Transmission 2Health News:Circumcision May Lift HIV Risk for Women 2Health News:Dry Eye Syndrome Affects Visual Functions 2Health News:Combination of Depression and Type-2-diabetes Lethal for Heart Patients 2Health News:Health Care Systems for Critically Ill Patients Need Restructuring 2
Serrated handle with polished finish. Non-magnetic. Straight tips: Delicate 11 mm. Most popular size or model....
Straight crisscross serrated tips. Flat handle with holes and polished finish....
1 x 2 teeth, cross serrated 5 mm 60 degree angled platform. Round knurled handle with polished finish....
5 mm tying platform, serrated cross action handle with polished finish. Teeth: 0.10 mm, 1 x 2 set at 90 degrees....
Medicine Products: